A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nexstar Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
HIV infection.
Advanced Kaposi's sarcoma.
Prior Medication:
Allowed:
Prior intralesional vinblastine.
You may not be if
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Acute intercurrent infection other than genital herpes.
Uncompensated cardiovascular, hepatic, renal, or pulmonary disease unrelated to Kaposi's sarcoma.
Symptomatic peripheral neuropathy.
Any condition that compromises ability to give informed consent or complete the study.
Concurrent Medication:
Excluded:
Concurrent ganciclovir.
Patients with the following prior conditions are excluded:
Symptomatic AIDS-defining opportunistic infection within 2 weeks of entry.
History of malignancy other than Kaposi's sarcoma, basal cell carcinoma, or carcinoma in situ of the cervix.
Prior Medication:
Excluded:
Prior systemic chemotherapy.
Intralesional therapies within 7 days prior to study entry.
Growth factors (G-CSF or GM-CSF), immune modifiers, or investigational agents within 14 days prior to study entry.
Interferon preparations (alpha or beta) within 28 days prior to study entry.
Prior Treatment:
Excluded within 7 days prior to study entry:
Radiation.
Local therapies (e.g., cryotherapy).
Clareo Health | A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
